Workflow
六味地黄丸系列
icon
Search documents
港股异动 | 同仁堂科技(01666)绩后跌超5% 上半年净利润3.39亿元 同比减少21.01%
Zhi Tong Cai Jing· 2025-08-27 03:28
消息面上,同仁堂科技发布中期业绩,该集团取得收入37.39亿元人民币,同比减少7.69%;公司所有者 应占净利润3.39亿元,同比减少21.01%。报告期内,集团销售额超过人民币1亿元的产品4个;销售额介 于人民币1000万元至人民币1亿元之间的产品28个;销售额介于人民币500万元至人民币1000万元之间的 产品10个。 智通财经APP获悉,同仁堂科技(01666)绩后跌超5%,截至发稿,跌5.65%,报5.01港元,成交额1835.62 万港元。 (原标题:港股异动 | 同仁堂科技(01666)绩后跌超5% 上半年净利润3.39亿元 同比减少21.01%) 主导产品中,六味地黄丸系列销售收入较上年同期增长约47.99%、金匮肾气系列销售收入较上年同期 增长约19.55%,京制牛黄解毒片系列销售收入较上年同期增长约4.03%,感冒清热颗粒系列及生脉饮口 服液系列销售收入较上年同期有所下降。但受益于"大品种战略",壮腰健肾丸系列、知柏地黄丸系列及 归芍地黄丸系列等产品的销售收入均较上年同期实现双位数增长。 ...
同仁堂科技绩后跌超5% 上半年净利润3.39亿元 同比减少21.01%
Zhi Tong Cai Jing· 2025-08-27 03:17
同仁堂(600085)科技(01666)绩后跌超5%,截至发稿,跌5.65%,报5.01港元,成交额1835.62万港 元。 消息面上,同仁堂科技发布中期业绩,该集团取得收入37.39亿元人民币,同比减少7.69%;公司所有者 应占净利润3.39亿元,同比减少21.01%。报告期内,集团销售额超过人民币1亿元的产品4个;销售额介 于人民币1000万元至人民币1亿元之间的产品28个;销售额介于人民币500万元至人民币1000万元之间的 产品10个。 主导产品中,六味地黄丸系列销售收入较上年同期增长约47.99%、金匮肾气系列销售收入较上年同期 增长约19.55%,京制牛黄解毒片系列销售收入较上年同期增长约4.03%,感冒清热颗粒系列及生脉饮口 服液系列销售收入较上年同期有所下降。但受益于"大品种战略",壮腰健肾丸系列、知柏地黄丸系列及 归芍地黄丸系列等产品的销售收入均较上年同期实现双位数增长。 ...
同仁堂科技:聚力创新筑根基 高质量发展态势稳固
Zheng Quan Ri Bao Wang· 2025-08-26 13:17
Core Viewpoint - Tongrentang Technology achieved significant growth in the first half of the year, with revenue of 3.739 billion yuan and a net profit of 484 million yuan, indicating a strong commitment to high-quality and sustainable development through various initiatives [1] Group 1: Financial Performance - In the first half of the year, Tongrentang Technology reported revenue of 3.739 billion yuan and a net profit of 484 million yuan, with the profit attributable to owners amounting to 339 million yuan [1] - The company’s core products showed strong sales performance, with four products exceeding 100 million yuan in sales and 28 products in the 10 million to 100 million yuan range [3] Group 2: Product Strategy - The company is focusing on enhancing the profitability of its core products, particularly the Liuwei Dihuang Wan series, which saw a revenue increase of approximately 47.99% year-on-year [3] - The implementation of a "big variety strategy" has led to significant sales growth across multiple product lines, including the Jinkui Shenqi series and Jingzhi Niuhuang Jiedu Pian series, which grew by 19.55% and 4.03% respectively [3] Group 3: International Expansion - Tongrentang Guoyao, a subsidiary, has become a key growth driver, achieving sales of 702 million yuan, a year-on-year increase of 15.99% [4] - The subsidiary is actively expanding its online and offline sales channels, focusing on key products like the broken wall Ganoderma lucidum spore powder capsules [4] Group 4: Supply Chain and Certification - The company’s six raw material production subsidiaries are strengthening the supply chain by stabilizing planting areas and enhancing quality standards, with several medicinal materials receiving organic certification [5][6] Group 5: Innovation and Marketing - The company is reforming its marketing strategy by implementing a "six control" management goal and streamlining its distribution channels to enhance market responsiveness [7][8] - Tongrentang Technology is advancing its smart manufacturing capabilities by integrating intelligent filling and automatic packaging technologies into its production lines [8] Group 6: Research and Development - The company is leading a project to improve national pharmacopoeia standards, aiming to establish a quality evaluation system based on clinical efficacy [8] - Ongoing clinical research on major products like Jinkui Shenqi Wan and the promising new drug Qishen Granules is expected to drive future growth [8]
同仁堂科技(01666.HK)公布中期业绩 将坚定不移落实大品种战略
Ge Long Hui· 2025-08-26 12:24
未来,集团将继续践行「提质增效」年的工作安排,紧扣改革创新这一核心主线,秉持稳中求进的总基 调开展工作。通过全力推行覆盖全流程、全链条、全级次的精益管理模式,坚定信心、奋勇前行,以实 干推动集团高质量发展,为开启「十五五」的崭新篇章筑牢根基。 下半年,集团的营销工作将紧扣「转观念、讲协调、提质效、强执行、重管理、树信心」这一核心要 点,大力强化「全员营销」意识,坚定不移落实「大品种战略」,从各个环节提升经营质量。同时,严 格把控市场秩序,以创新为驱动,积极开拓市场,达成创收、创利目标,推动市场营销工作迈向崭新台 阶。 格隆汇8月26日丨同仁堂科技(01666.HK)发布公告,截至2025年6月30日止六个月期间,集团销售收入为 人民币373,850.3万元,实现净利润达人民币48,403.0万元。期间集团的毛利率为38.16%(上年同期: 37.95%)。 于报告期内,集团销售额超过人民币一亿元的产品四个;销售额介于人民币一千万元至人民币一亿元之 间的产品二十八个;销售额介于人民币五百万元至人民币一千万元之间的产品十个。主导产品中,六味 地黄丸系列销售收入较上年同期增长约47.99%、金匮肾气系列销售收入较上 ...
同仁堂科技发布中期业绩,股东应占净利润3.39亿元,同比减少21.01%
Zhi Tong Cai Jing· 2025-08-26 11:34
同仁堂(600085)科技(01666)发布截至2025年6月30日止6个月中期业绩,该集团取得收入人民币37.39 亿元(单位下同),同比减少7.69%;公司所有者应占净利润3.39亿元,同比减少21.01%;每股基本收益0.26 元。 公告称,销售收入及净利润减少主要由于营销改革深入推进,加速市场库存周转,优化库存结构,市场 秩序逐步向好,随着改革的推进,经营质量将稳步提升,为持续高质量发展奠定坚实基础。 于报告期内,集团销售额超过人民币1亿元的产品4个;销售额介于人民币1000万元至人民币1亿元之间的 产品28个;销售额介于人民币500万元至人民币1000万元之间的产品10个。主导产品中,六味地黄丸系列 销售收入较上年同期增长约47.99%、金匮肾气系列销售收入较上年同期增长约19.55%,京制牛黄解毒 片系列销售收入较上年同期增长约4.03%,感冒清热颗粒系列及生脉饮口服液系列销售收入较上年同期 有所下降。但受益于"大品种战略",壮腰健肾丸系列、知柏地黄丸系列及归芍地黄丸系列等产品的销售 收入均较上年同期实现双位数增长。 ...
同仁堂科技(01666)发布中期业绩,股东应占净利润3.39亿元,同比减少21.01%
智通财经网· 2025-08-26 11:31
智通财经APP讯,同仁堂科技(01666)发布截至2025年6月30日止6个月中期业绩,该集团取得收入人民币 37.39亿元(单位下同),同比减少7.69%;公司所有者应占净利润3.39亿元,同比减少21.01%;每股基本收益 0.26元。 于报告期内,集团销售额超过人民币1亿元的产品4个;销售额介于人民币1000万元至人民币1亿元之间的 产品28个;销售额介于人民币500万元至人民币1000万元之间的产品10个。主导产品中,六味地黄丸系列 销售收入较上年同期增长约47.99%、金匮肾气系列销售收入较上年同期增长约19.55%,京制牛黄解毒 片系列销售收入较上年同期增长约4.03%,感冒清热颗粒系列及生脉饮口服液系列销售收入较上年同期 有所下降。但受益于"大品种战略",壮腰健肾丸系列、知柏地黄丸系列及归芍地黄丸系列等产品的销售 收入均较上年同期实现双位数增长。 公告称,销售收入及净利润减少主要由于营销改革深入推进,加速市场库存周转,优化库存结构,市场 秩序逐步向好,随着改革的推进,经营质量将稳步提升,为持续高质量发展奠定坚实基础。 ...
同仁堂科技:“聚焦”战役 提升营销效能
Core Insights - In Q1 2025, Tongrentang Technology Company focused on market demand, enhancing product variety and channel development to stimulate marketing momentum [1] Group 1: Product Strategy - The company emphasized "focusing" on major products, directing promotional resources towards key varieties such as Yao Medicine 300 Years, Ejiao, and children's medicine, creating a clear product structure [1] - Core products like Xihuang Pill, Jingzhi Niuhuang Jiedu Pian, and Liuwuwei Dihuang Wan series have optimized pricing systems and operational strategies, achieving coverage in over 30 provinces [9] Group 2: Marketing Initiatives - The "Flag Planting Action" marketing campaign covered 10 key provinces, conducting 206 events and nearly 1500 terminal promotion activities, successfully enhancing product shelf presence and awareness [9] - The company targeted younger audiences with innovative marketing strategies, such as the "Beijing Tongrentang Super Good Pill" campaign during the JD Super Brand Day, appealing to their health-conscious yet skeptical mindset [11] Group 3: Community Engagement - The company engaged in community education about product knowledge, leveraging events like the Winter Olympics to promote health trends, particularly in Harbin [11][14] - Creative marketing slogans and campaigns, such as the AI-themed short films, resonated with younger demographics, making products like Jingzhi Niuhuang Jiedu Pian and Ejiao popular during the spring health season [12][14]